On June 25, 2026, Avidity Biosciences, Inc. shared that they have submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval of delpacibart zotadirsen (also known as “del-zota” or AOC 1044) as a treatment option for people living with Duchenne muscular dystrophy (DMD) who have a genetic variant that may be treated through exon 44 skipping (DMD44).
Please view their community letter by clicking here.